{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T05:02:23Z","timestamp":1779858143917,"version":"3.53.1"},"reference-count":35,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,31]],"date-time":"2025-07-31T00:00:00Z","timestamp":1753920000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100008741","name":"European League Against Rheumatism","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008741","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002553","name":"Aid for Cancer Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002553","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ard.eular.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of the Rheumatic Diseases"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.ard.2025.07.024","type":"journal-article","created":{"date-parts":[[2025,8,22]],"date-time":"2025-08-22T11:16:56Z","timestamp":1755861416000},"page":"1801-1810","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["SLE classification criteria item relationships: implications on SLE as a disease entity"],"prefix":"10.1016","volume":"84","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4471-8375","authenticated-orcid":false,"given":"Martin","family":"Aringer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franziska","family":"Szelinski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6478-7725","authenticated-orcid":false,"given":"Thomas","family":"D\u00f6rner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8972-9388","authenticated-orcid":false,"given":"Karen H.","family":"Costenbader","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sindhu R.","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.ard.2025.07.024_bib0001","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1136\/ard-2022-223741","article-title":"Pathogenesis of systemic lupus erythematosus: risks, mechanisms and therapeutic targets","volume":"82","author":"Crow","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ard.2025.07.024_bib0002","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1146\/annurev-immunol-101921-042422","article-title":"Systemic lupus erythematosus pathogenesis: interferon and beyond","volume":"41","author":"Caielli","year":"2023","journal-title":"Annu Rev Immunol"},{"issue":"2","key":"10.1016\/j.ard.2025.07.024_bib0003","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1097\/BOR.0000000000000922","article-title":"An update on autoantibodies in systemic lupus erythematosus","volume":"35","author":"G\u00f3mez-Ba\u00f1uelos","year":"2023","journal-title":"Curr Opin Rheumatol"},{"issue":"9","key":"10.1016\/j.ard.2025.07.024_bib0004","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1136\/annrheumdis-2018-214819","article-title":"2019 European League Against Rheumatism\/American College of Rheumatology classification criteria for systemic lupus erythematosus","volume":"78","author":"Aringer","year":"2019","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"10.1016\/j.ard.2025.07.024_bib0005","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1002\/art.40930","article-title":"2019 European League Against Rheumatism\/American College of Rheumatology classification criteria for systemic lupus erythematosus","volume":"71","author":"Aringer","year":"2019","journal-title":"Arthritis Rheumatol"},{"issue":"7","key":"10.1016\/j.ard.2025.07.024_bib0006","doi-asserted-by":"crossref","first-page":"721","DOI":"10.3899\/jrheum.180478","article-title":"Use of consensus methodology to determine candidate items for systemic lupus erythematosus classification criteria","volume":"46","author":"Johnson","year":"2019","journal-title":"J Rheumatol"},{"issue":"1","key":"10.1016\/j.ard.2025.07.024_bib0007","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1002\/art.40674","article-title":"Brief report: how do patients with newly diagnosed systemic lupus erythematosus present? A multicenter cohort of early systemic lupus erythematosus to inform the development of new classification criteria","volume":"71","author":"Mosca","year":"2019","journal-title":"Arthritis Rheumatol"},{"issue":"3","key":"10.1016\/j.ard.2025.07.024_bib0008","first-page":"167","article-title":"Morbidity and mortality in systemic lupus erythematosus during a 5-year period. A multicenter prospective study of 1,000 patients","volume":"78","author":"Cervera","year":"1999","journal-title":"European Working Party on Systemic Lupus Erythematosus. Medicine (Baltimore)."},{"issue":"12","key":"10.1016\/j.ard.2025.07.024_bib0009","doi-asserted-by":"crossref","first-page":"1820","DOI":"10.1002\/acr.24078","article-title":"Associations between classification criteria items in systemic lupus erythematosus","volume":"72","author":"Touma","year":"2020","journal-title":"Arthritis Care Res"},{"issue":"4","key":"10.1016\/j.ard.2025.07.024_bib0010","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1002\/acr.23317","article-title":"Developing and refining new candidate criteria for systemic lupus erythematosus classification: an international collaboration","volume":"70","author":"Tedeschi","year":"2018","journal-title":"Arthritis Care Res(Hoboken)"},{"issue":"10","key":"10.1016\/j.ard.2025.07.024_bib0011","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1136\/annrheumdis-2020-217162","article-title":"Performance of the 2019 EULAR\/ACR classification criteria for systemic lupus erythematosus in early disease, across sexes and ethnicities","volume":"79","author":"Johnson","year":"2020","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"10.1016\/j.ard.2025.07.024_bib0012","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1136\/annrheumdis-2020-219373","article-title":"European League Against Rheumatism (EULAR)\/American College of Rheumatology (ACR) SLE classification criteria item performance","volume":"80","author":"Aringer","year":"2021","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"10.1016\/j.ard.2025.07.024_bib0013","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1080\/1744666X.2023.2292188","article-title":"SLE criteria are by necessity still based on clinical (and immunological) criteria items","volume":"20","author":"Aringer","year":"2024","journal-title":"Expert Rev Clin Immunol"},{"issue":"9767","key":"10.1016\/j.ard.2025.07.024_bib0014","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/S0140-6736(10)61354-2","article-title":"Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial","volume":"377","author":"Navarra","year":"2011","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.ard.2025.07.024_bib0015","doi-asserted-by":"crossref","first-page":"3918","DOI":"10.1002\/art.30613","article-title":"A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus","volume":"63","author":"Furie","year":"2011","journal-title":"Arthritis Rheum"},{"issue":"5","key":"10.1016\/j.ard.2025.07.024_bib0016","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1002\/art.40049","article-title":"Efficacy and safety of subcutaneous belimumab in systemic lupus erythematosus: a fifty-two-week randomized, double-blind, placebo-controlled study","volume":"69","author":"Stohl","year":"2017","journal-title":"Arthritis Rheumatol"},{"issue":"9","key":"10.1016\/j.ard.2025.07.024_bib0017","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1136\/annrheumdis-2016-210882","article-title":"Enteric-coated mycophenolate sodium versus azathioprine in patients with active systemic lupus erythematosus: a randomised clinical trial","volume":"76","author":"Ordi-Ros","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"10.1016\/j.ard.2025.07.024_bib0018","doi-asserted-by":"crossref","first-page":"e208","DOI":"10.1016\/S2665-9913(19)30076-1","article-title":"Type I interferon inhibitor anifrolumab in active systemic lupus erythematosus (TULIP-1): a randomised, controlled, phase 3 trial","volume":"1","author":"Furie","year":"2019","journal-title":"Lancet Rheumatol"},{"issue":"3","key":"10.1016\/j.ard.2025.07.024_bib0019","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMoa1912196","article-title":"Trial of anifrolumab in active systemic lupus erythematosus","volume":"382","author":"Morand","year":"2020","journal-title":"N Engl J Med"},{"issue":"10381","key":"10.1016\/j.ard.2025.07.024_bib0020","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1016\/S0140-6736(22)02607-1","article-title":"Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 3 trial (SLE-BRAVE-I)","volume":"401","author":"Morand","year":"2023","journal-title":"Lancet"},{"issue":"10381","key":"10.1016\/j.ard.2025.07.024_bib0021","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/S0140-6736(22)02546-6","article-title":"Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 3 trial (SLE-BRAVE-II)","volume":"401","author":"Petri","year":"2023","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.ard.2025.07.024_bib0022","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbspin.2024.105760","article-title":"Cluster analysis of clinical manifestations assigns systemic lupus erythematosus-phenotype subgroups: a multicentre study on 440 patients","volume":"91","author":"Mariette","year":"2024","journal-title":"Joint Bone Spine"},{"issue":"7","key":"10.1016\/j.ard.2025.07.024_bib0023","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1136\/ard-2022-223808","article-title":"Machine learning identifies clusters of longitudinal autoantibody profiles predictive of systemic lupus erythematosus disease outcomes","volume":"82","author":"Choi","year":"2023","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"10.1016\/j.ard.2025.07.024_bib0024","doi-asserted-by":"crossref","first-page":"2406","DOI":"10.3390\/jcm11092406","article-title":"Three clinical clusters identified through hierarchical cluster analysis using initial laboratory findings in Korean patients with systemic lupus erythematosus","volume":"11","author":"Jung","year":"2022","journal-title":"J Clin Med"},{"issue":"1","key":"10.1016\/j.ard.2025.07.024_bib0025","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1002\/acr2.11343","article-title":"Four systemic lupus erythematosus subgroups, defined by autoantibodies status, differ regarding HLA-DRB1 genotype associations and immunological and clinical manifestations","volume":"4","author":"Diaz-Gallo","year":"2022","journal-title":"ACR Open Rheumatol"},{"issue":"14","key":"10.1016\/j.ard.2025.07.024_bib0026","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1177\/0961203309345767","article-title":"Prognostically distinct clinical patterns of systemic lupus erythematosus identified by cluster analysis","volume":"18","author":"To","year":"2009","journal-title":"Lupus"},{"issue":"5","key":"10.1016\/j.ard.2025.07.024_bib0027","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.semnephrol.2015.08.005","article-title":"The role of anti-DNA antibodies in the development of lupus nephritis: a complementary, or alternative, viewpoint?","volume":"35","author":"Goilav","year":"2015","journal-title":"Semin Nephrol"},{"issue":"5","key":"10.1016\/j.ard.2025.07.024_bib0028","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1097\/BOR.0000000000000523","article-title":"Autoimmune haemolytic anaemia and autoimmune thrombocytopenia in childhood-onset systemic lupus erythematosus: updates on pathogenesis and treatment","volume":"30","author":"Neely","year":"2018","journal-title":"Curr Opin Rheumatol"},{"issue":"1","key":"10.1016\/j.ard.2025.07.024_bib0029","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2014-000078","article-title":"Haematological manifestations of lupus","volume":"2","author":"Fayyaz","year":"2015","journal-title":"Lupus Sci Med"},{"key":"10.1016\/j.ard.2025.07.024_bib0030","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1136\/ard-2023-224609","article-title":"2023 ACR\/EULAR antiphospholipid syndrome classification criteria","volume":"28","author":"Barbhaiya","year":"2023","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"10.1016\/j.ard.2025.07.024_bib0031","first-page":"2141","article-title":"Fever in systemic lupus erythematosus: associated clinical features and genetic factors","volume":"40","author":"Olivieri","year":"2022","journal-title":"Clin Exp Rheumatol"},{"issue":"2","key":"10.1016\/j.ard.2025.07.024_bib0032","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1007\/s00296-016-3630-0","article-title":"The prevalence and risk factors for serositis in patients with systemic lupus erythematosus: a cross-sectional study","volume":"37","author":"Liang","year":"2017","journal-title":"Rheumatol Int"},{"issue":"1","key":"10.1016\/j.ard.2025.07.024_bib0033","doi-asserted-by":"crossref","first-page":"7617","DOI":"10.1038\/s41598-017-08099-3","article-title":"Anti-SmD1 antibodies are associated with renal disorder, seizures, and pulmonary arterial hypertension in Chinese patients with active SLE","volume":"7","author":"Hu","year":"2017","journal-title":"Sci Rep"},{"issue":"1","key":"10.1016\/j.ard.2025.07.024_bib0034","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/s13075-020-02407-5","article-title":"Chinese SLE Treatment and Research Group Registry (CSTAR) XIII: Prevalence and risk factors for chronic scarring alopecia in patients with systemic lupus erythematosus","volume":"23","author":"Xiang","year":"2021","journal-title":"Arthritis Res Ther"},{"issue":"2","key":"10.1016\/j.ard.2025.07.024_bib0035","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1093\/rheumatology\/kev311","article-title":"The frequency and outcome of lupus nephritis: results from an international inception cohort study","volume":"55","author":"Hanly","year":"2016","journal-title":"Rheumatology (Oxford)"}],"container-title":["Annals of the Rheumatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496725042943?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496725042943?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T04:13:34Z","timestamp":1779855214000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003496725042943"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":35,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["S0003496725042943"],"URL":"https:\/\/doi.org\/10.1016\/j.ard.2025.07.024","relation":{},"ISSN":["0003-4967"],"issn-type":[{"value":"0003-4967","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"SLE classification criteria item relationships: implications on SLE as a disease entity","name":"articletitle","label":"Article Title"},{"value":"Annals of the Rheumatic Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ard.2025.07.024","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier B.V. on behalf of European Alliance of Associations for Rheumatology (EULAR).","name":"copyright","label":"Copyright"}]}}